Refer to the following important safety details for information on intended use, potential side effects and risks, considerations for specific groups, and possible drug interactions linked to the prescription treatments mentioned.
Reporting Side Effects
Riovie encourages users to promptly report any side effects or adverse reactions to a licensed healthcare provider and the pharmacy that dispensed the medication. To report suspected reactions to these medications, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
For emergencies, call 911 or go to your nearest emergency department.
Advertisements by Riovie
All advertisements from riovie.com are paid for by Riovie and are intended to market Riovie’s services. Some advertisements may feature paid actors or dramatizations. When real Riovie customers or endorsements are included, this will be clearly disclosed. Individual results may vary, and specific outcomes are not guaranteed.
Riovie’s Role
Riovie connects users with licensed healthcare providers for evaluations regarding the suitability of the treatments advertised. It may also assist with prescription coordination through an external pharmacy network.
Riovie acts as a managed services provider and does not offer medical advice, fill prescriptions, or function as a licensed healthcare facility or pharmacy. Instead, it provides technology and administrative support to enable medical consultations and prescription logistics. For further details, see Riovie’s Terms of Service.
Promotional Offers on riovie.com
Occasionally, the website may present promotional pricing or special introductory offers. Pricing may change at any time due to supply or market conditions at the discretion of riovie.com. Introductory or promotional pricing, including “first month” offers, applies only to the plan and product listed at the time of purchase.
Prescriptions and Medications
Prescription drugs require evaluation and approval by a qualified healthcare provider, and issuance is solely at the provider’s discretion. Access to treatment plans and medications is not assured.
Prescriptions issued through Riovie may be filled by licensed pharmacies within its affiliated network.
All prescription medications involve potential risks. Please review all associated safety details and consult your provider for personalized advice.
Compounded Drug Formulations
In certain situations, healthcare providers may prescribe compounded medications, which are custom-prepared by licensed compounding pharmacies based in the U.S. These medications are not FDA-approved for safety or effectiveness but may be used when alternatives are not available or appropriate.
Riovie helps facilitate compounded medication fulfillment via its partner pharmacy network. These formulations are personalized to meet individual patient requirements and may differ from commercial products.
Trademark Notice
Riovie is not affiliated with, sponsored by, or endorsed by the manufacturer of any brand-name medication. Any brand names referenced are the property of their respective owners and are used for identification only.
Contact Information
For any questions about Riovie’s services or advertising content, please reach out to support@riovie.com.
PT-141 — Subcutaneous Injection
Important Safety Information Regarding Compounded PT-141 (Bremelanotide)
Please be aware that compounded drugs are not FDA-approved and do not undergo clinical studies to evaluate for safety and efficacy. Your healthcare provider may prescribe compounded PT-141 based on your medical consultation.
PT-141 (bremelanotide) is a melanocortin receptor agonist. It acts on central pathways involved in sexual desire and arousal rather than on blood flow. Riovie prescribes it for women only. An FDA-approved bremelanotide product is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women; compounded PT-141 is prescribed at a provider’s discretion and is not a treatment for low desire caused by a co-existing medical or psychiatric condition, by relationship problems, or by the effects of another medication.
Do not use PT-141 if:
- You have uncontrolled high blood pressure or known cardiovascular disease.
- You have had a serious allergic reaction to bremelanotide or to any component of the formulation.
- You are pregnant, trying to become pregnant, or breastfeeding. Stop and contact your provider if you think you may be pregnant.
Inform your healthcare provider if you:
- Have high blood pressure of any degree, or any heart or circulatory condition — each dose transiently raises blood pressure and lowers heart rate.
- Take oral naltrexone. PT-141 can significantly reduce naltrexone levels, which matters if you take it for alcohol or opioid dependence.
- Take any medication where a consistent blood level matters — PT-141 can slow stomach emptying and delay absorption.
- Have kidney or liver disease.
- Have darker skin or a history of hyperpigmentation, which raises the risk of skin darkening.
Serious risks include:
- Transient increases in blood pressure and decreases in heart rate after each dose
- Focal hyperpigmentation — darkening of the skin, gums, or face, which may not fully resolve after stopping and is more likely with frequent dosing
- Serious allergic reactions
- Reduced effect of oral naltrexone
Common side effects: nausea — the most frequently reported effect, usually strongest with the first dose — along with flushing, headache, vomiting, injection-site pain, redness or swelling, tiredness, dizziness, and nasal congestion.
Administration: Inject subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity, using aseptic technique and rotating sites. Use no more than one dose in any 24-hour period and no more than eight doses in a month. This medication is used as needed and is not taken on a daily schedule. Do not increase your dose or dosing frequency without speaking to your physician.
Monitoring: Your provider may ask you to monitor your blood pressure, and may review your response and any side effects before continuing treatment.
Reporting side effects: Contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
